Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancy. (June 2022)

• Record Type: Journal Article
• Authors: Scott, R; Parker, H; Mccartney, S; Harrow, P; Williams, D; Giles, I
• Is Part Of: Obstetric medicine. Volume 15:Number 2(2022)
• Page Start: 104
• Page End: 107
• Publication Date: 2022-06
• Subjects: Biosimilar -- pregnancy -- inflammatory -- rheumatology -- gastroenterology; Pregnancy -- Complications -- Periodicals; Obstetrics -- Periodicals; 618.2
• DOI: 10.1177/1753495X211028779
• Languages: English
• ISSNs: 1753-495X

Abstract

Background: Biosimilar tumour necrosis factor inhibitors (TNFi) are increasingly used to treat inflammatory immune-mediated disorders as they cost less than the originator biologic drug. More women are therefore becoming pregnant on biosimilar TNFi. This is the first paper to explore the safety and efficacy of biosimilar therapies in pregnancy. Methods: A retrospective review of clinical data reviewed pregnancy outcomes and inflammatory disease activity in 18 pregnancies where the mother was using a biosimilar TNFi at conception. Results: Biosimilar therapy was not associated with congenital abnormalities, preterm birth or other adverse pregnancy outcomes. Stopping biosimilar TNFi in pregnancy was associated with childbirth at an earlier gestation, as well as a flare of inflammatory disease in pregnancy or post-partum. Conclusions: Women and clinicians should feel confident in using biosimilar TNFi in early pregnancy, and continuing them through pregnancy to prevent flares in late pregnancy or the early post-partum.